Session » Abstracts: SLE – Diagnosis, Manifestations, & Outcomes III: Disease Activity
- 4:00PM-5:30PM
-
Abstract Number: 2555
Cluster Analysis Reveals Subgroups in Patients with Serologically Active Clinically Quiescent Systemic Lupus Erythematosus: Implication for Long-term Prognosis Prediction
- 4:00PM-5:30PM
-
Abstract Number: 2556
End-of-Life in Systemic Lupus Erythematosus Beset by Increased Flares and Higher Treatment Burden: Data from a Prospective Large Multinational Cohort
- 4:00PM-5:30PM
-
Abstract Number: 2552
Inflammatory Fibrosis Precedes Loss of Kidney Function in Lupus Nephritis
- 4:00PM-5:30PM
-
Abstract Number: 2553
Prevalence, Determinants and Outcomes of Target Attainment in SLE Patients with Clinically Active Disease in a Large Multinational Prospective Lupus Cohort
- 4:00PM-5:30PM
-
Abstract Number: 2551
Remission and Low Disease Activity (LDA) in Patients with SLE Treated with Belimumab (BEL): Results from a Large Integrated Analysis
- 4:00PM-5:30PM
-
Abstract Number: 2554
Validation of a Flare Risk Index Informed by Select Immune Mediators in Systemic Lupus Erythematosus in a Confirmatory Cohort